larotrectinib is well-tolerated in metastatic solid tumors
Published 4 years ago • 93 plays • Length 0:39Download video MP4
Download video MP3
Similar videos
-
1:20
updated data with larotrectinib in trk fusion-positive solid tumors
-
6:47
efficacy of trki–larotrectinib among tumor types
-
1:15
larotrectinib, a trk inhibitor for patients with solid tumors
-
7:14
larotrectinib for solid tumors with ntrk gene fusions
-
6:01
patient selection and responses to larotrectinib
-
3:21
drawing larotrectinib data from different tumor types
-
5:00
larotrectinib: a tumor-agnostic therapy
-
6:02
early development of trk inhibitor–larotrectinib
-
0:51
bi 907828: targeting mdm2 in solid tumors
-
6:51
entrectinib as treatment for ntrk-positive solid tumors
-
1:06
updated response findings with larotrectinib in trk cancers
-
2:14
treatment options for ntrk fusion–positive mcrc
-
7:05
targeted therapy shows continued promise in patients whose tumours had ntrk gene fusions
-
0:57
on203: the anti-oxmif antibody targeting solid tumors
-
3:02
larotrectinib for central nervous system cancers with trk fusions
-
4:54
safety and efficacy profile for trki–larotrectinib
-
1:17
ntrk-targeted therapy in colon cancer: dosing and management
-
4:36
trk inhibition: personal experience with larotrectinib
-
4:16
analyzing response rates with larotrectinib